Analysis of antibody response to HPV 16 and HPV 18 antigens in tunisian patients

Viral Immunology

Volumn 22, Issue 1, 2009, Pages 7-15

  Achour, Mongia ^a   Kahla, Saloua ^a   Zeghal, Dorra ^b   Kochbati, Lotfi ^c   Mongi, Maalej ^c   Zouari, Faouzia ^b   Oueslati, Ridha ^a,d,e  

^a Faculty of Sciences   (Tunisia)

^b Centre de Maternite et de Neonatologie Tunis   (Tunisia)

^c SALAH AZAIEZ INSTITUTE   (Tunisia)

^d Struggle and Prevention   (Tunisia)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; EARLY ANTIGEN; PROTEIN E6; PROTEIN E7; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS VECTOR;

ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CANCER PATIENT; CERVICAL INFLAMMATION; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; NONHUMAN; SEROLOGY; UTERINE CERVIX CANCER; VIRUS EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CAPSID PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; TUNISIA; UTERINE CERVICAL NEOPLASMS;

ESCHERICHIA COLI; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 60149094976     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2008.0009     Document Type: Article

References (26)

1. Ben Laabidi M: Evaluation de la prévention des cancers du col utérin par le frottis cervico-vaginal. Maghreb Médical 1996;308:36-40.
2. Bennis S, Meniar S, Amarti A, and Bijou A: La place du frottis cervico-vaginal dans le diagnostic du cancer du col utérin au Maroc, région Fès-Boulemane. East Mediterr Health J 2007;13:1-6.
3. Boulanger JC, Sevestre H, Bauville E, Ghighi C, Harlicot JP, and Gondry J: Epidemiology of HPV infection. Gynecol Obstet Fertil 2004;32:218-223.
4. Castellsagué X, Menéndez C, Loscertales MP, et al.: Human papillomavirus genotypes in rural Mozambique. Lancet 2001;358:1429-1430.
5. Clifford GM, Smith JS, Aguado T, and Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-105.
6. De Marco F, Houissa-Kchouk F, Khelifa R, and Marcante ML: High-risk HPV types in Tunisia. A pilot study reveals an unexpectedly high prevalence of types 58 and 82 and lack of HPV 18 among female prostitutes. J Med Virol 2006;78:950-953.
7. Dennis D, Jeff Van D, Sonela S, et al.: Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005;12:959-969.
8. Di Bonito P, Grasso F, Mochi1 S, et al.: Serum antibody response to human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect Agents Cancer 2006;1:1-9.
9. Dillner J, and Brown DR: Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine? Expert Rev Mol Med 2004;9:1-21.
10. Goldie SJ, Kim JJ, Kobus K, et al.: Cost-effectiveness of HPV 16 and 18 vaccination in Brazil. Vaccine 2007;25):6257-6270.
11. Hassen E, Chaieb A, Bouaouina N, Khairi H, Remadi S, and Chouchane L: Strategies for Detection of Papillomavirus Specific Antibodies. Mod Asp Immunobiol 2001;2:8-12.
12. Howard DS, Gregory DK, Peter JF, et al.: HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer 1999;80:339-344.
13. Ho GY, Bierman R, Beardsley L, Chang CJ, and Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
14. Lehtinen M, Pawlita M, Zumbach K, et al.: Evaluation of antibody response to human papillomavirus early proteins in women whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol 2003;188:49-55.
15. Maalej M, Ben Youssef A, Ben Abdallah M, Sellami D, and Benna F: Epidémiologie du cancer du col de l'utérus en Tunisie. Maghreb Médical 1991;242:12-17.
16. Maalej M, Mrad K, Kochbati L, Guigua A, Ben Abdallah M, Ben Ayed F, and Ben Romdhane K: Cervical cancer in Tunisia: an epidemiological, clinical and pathological study. Eur J Obstet Gynecol Reprod Biol 2004;113:226-228.
17. Meschede W, Zumbach K, Braspenneng J, et al.: Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998;36:475-480.
18. Parkin D: The epidemiological basis for evaluation screening policies. In: New Developments in Cervical Cancer Screening and Prevention. (Franco E, and Monsonego J, eds.). Oxford: Blackwell Science, 1997.
19. Parkin DM: Personal communication. IARC 2000.
20. Rylander AE, Larsson B, Strand A, Silfversvard C, and Wilander E: The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001;37:246-250.
21. Schiffman M, Herrero R, Hildesheim A, et al.: HPV DNA testing in cervical cancer screening. JAMA 2000;283:87-93.
22. Schmitt M, Bravo IG, Snijders PJ, Gissman L, Pawlita M, and Waterboer M: Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504-512.
23. Sehr P, Zumbach K, and Pawlita M: A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001;253:153-162.
24. Sehr P, Muller M, Hopfl R, Widschwendter A, and Pawlita M: HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002;106:61-70.
25. Waterboer T, Sehr P, Michael KM, et al.: Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 2005;51:1845-1853.
26. Waterboer T, Sehr P, and Pawlita M: Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006;309:200-204.